Key Documents

View All Documentation

F8791

5-Fluoro-5′-deoxyuridine

Name: 5-Fluoro-5′-deoxyuridine
Brand: SIGMA

Synonym(s):

Doxifluridine, 5′dFUrd

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₉H₁₁FN₂O₅

CAS Number:

3094-09-5

Molecular Weight:

246.19

NACRES:

NA.77

PubChem Substance ID:

24278444

UNSPSC Code:

12352200

EC Number:

221-440-1

MDL number:

MFCD00866530

Quality level:

200

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Quality Level

200

SMILES string

C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O

InChI

1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1

InChI key

ZWAOHEXOSAUJHY-ZIYNGMLESA-N

Description

Biochem/physiol Actions

Doxifluridine is an antitumor agent efficient in tumors, cell lines or in fibroblasts transformed by H-ras or trk oncogenes. Possesses anticachectic activity which is independent of its antiproliferative activity.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000463711

0000404421

0000202369

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Product Information Sheet - F8791

Product Information Sheet

Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts.

Yasuko Naganuma et al.

Cancer science, 102(8), 1545-1552 (2011-06-03)

Uterine carcinosarcoma is a highly aggressive gynecological neoplasm that responds poorly to conventional chemotherapy and radiotherapy. Metronomic chemotherapy is accepted as a new approach for cancer treatment, and its underlying mechanism seems to involve the suppression of angiogenesis. However, the

Nearly monodispersed core-shell structural Fe3O4@DFUR-LDH submicro particles for magnetically controlled drug delivery and release.

Dengke Pan et al.

Chemical communications (Cambridge, England), 47(3), 908-910 (2010-11-17)

Nearly monodispersed magnetic Fe(3)O(4)@DFUR-LDH submicro particles containing the anticancer agent DFUR were prepared via a coprecipitation-calcination-reconstruction strategy of LDH materials over the surface of Fe(3)O(4) particles, and present well-defined core-shell structure, strong magnetization and obvious magnetically controlled drug delivery and

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.

Maria Ait-Tihyaty et al.

Breast cancer research and treatment, 133(1), 217-226 (2011-09-15)

Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer. It is metabolized first in the liver by carboxylesterases to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR), which is subsequently converted to 5'-deoxy-5-fluorouridine ribose (5'-DFUR) by cytidine

View All Related Papers

Global Trade Item Number

SKU	GTIN
F8791-100MG	04061833024140
F8791-250MG	04061833621103
F8791-25MG	04061833024164